Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Jan;17(1):88-92.
doi: 10.5863/1551-6776-17.1.88.

Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab)

Affiliations
Case Reports

Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab)

Mai K Elmallah et al. J Pediatr Pharmacol Ther. 2012 Jan.

Abstract

Omalizumab is a recombinant DNA-derived humanized immunoglobulin G (IgG) anti-IgE monoclonal antibody approved for use in patients with allergic asthma. However, it is not approved for allergic bronchopulmonary aspergillosis (ABPA). Conflicting reports exist about the effects of omalizumab on ABPA in patients with cystic fibrosis (CF). We report 2 patients with CF treated with omalizumab, in whom frequency of ABPA exacerbations was markedly reduced with treatment. Additionally, hospitalizations were reduced from 5 per year to once in 18 months in the first patient and from twice to once per year in the second patient. Free IgE decreased by 87.9% after 6 months of therapy in the first patient and by 95.6% after 7 months of therapy in the second patient. Neither of the two patients had evidence of asthma. Omalizumab may be useful in treating ABPA in patients with CF, and including free IgE in monitoring the response to therapy will be helpful.

Keywords: Allergic bronchopulmonary aspergillosis; cystic fibrosis; free IgE; omalizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
FEV1 (solid diamonds with solid line), FVC (solid circles with solid line), hospitalizations (solid triangles), and omalizumab injections (solid squares) over time for Case 1. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity
Figure 2.
Figure 2.
Free (dashed line) and total IgE (solid line) concentrations for Case 1.
Figure 3.
Figure 3.
FEV1 (dashed line), FVC (solid line), hospitalizations (solid triangles), and omalizumab injections (solid squares) over time for Case 2. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

References

    1. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37(suppl 3):S225–S264. - PubMed
    1. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;2011:843763. - PMC - PubMed
    1. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab) Pediatr Pulmonol. 2008;43(12):1249–1251. - PubMed
    1. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol. 2008;43(6):607–610. - PubMed
    1. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ASPA exacerbations in CF patients. Pediatr Pulmonol. 2009;44(5):516. - PubMed

Publication types

LinkOut - more resources